Relevant bibliographies by topics / Allergen immunotherapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Allergen immunotherapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Allergen immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Allergen immunotherapy"

1

He, Ying, Xueting Liu, Yuyi Huang, Zehong Zou, Huifang Chen, He Lai, Lida Zhang, et al. "Reduction of the Number of Major Representative Allergens: From Clinical Testing to 3-Dimensional Structures." Mediators of Inflammation 2014 (2014): 1–11. http://dx.doi.org/10.1155/2014/291618.

Full text
Abstract:
Vast amounts of allergen sequence data have been accumulated, thus complicating the identification of specific allergenic proteins when performing diagnostic allergy tests and immunotherapy. This study aims to rank the importance/potency of the allergens so as to logically reduce the number of allergens and/or allergenic sources. Meta-analysis of 62 allergenic sources used for intradermal testing on 3,335 allergic patients demonstrated that in southern China, mite, sesame, spiny amaranth,Pseudomonas aeruginosa, and house dust account for 88.0% to 100% of the observed positive reactions to the 62 types of allergenic sources tested. TheKolmogorov-SmironovTest results of the website-obtained allergen data and allergen family featured peptides suggested that allergen research in laboratories worldwide has been conducted in parallel on many of the same species. The major allergens were reduced to 21 representative allergens, which were further divided into seven structural classes, each of which contains similar structural components. This study therefore has condensed numerous allergenic sources and major allergens into fewer major representative ones, thus allowing for the use of a smaller number of allergens when conducting comprehensive allergen testing and immunotherapy treatments.
APA, Harvard, Vancouver, ISO, and other styles
2

Lei, Dawn K., and Carol Saltoun. "Allergen immunotherapy: definition, indications, and reactions." Allergy and Asthma Proceedings 40, no. 6 (November 1, 2019): 369–71. http://dx.doi.org/10.2500/aap.2019.40.4249.

Full text
Abstract:
Specific allergen immunotherapy is the administration of increasing amounts of specific allergens to which the patient has type I immediate hypersensitivity. It is a disease-modifying therapy, indicated for the treatment of allergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera hypersensitivity. Specific immunoglobulin E (IgE) antibodies for appropriate allergens for immunotherapy must be documented. Indications for allergen immunotherapy include (1) inadequate symptom control despite pharmacotherapy and avoidance measures; (2) a desire to reduce the morbidity from allergic rhinitis and/or asthma, or reduce the risk of anaphylaxis from a future insect sting; (3) when the patient experiences undesirable adverse effects from pharmacotherapy; and (4) when avoidance is not possible. Several studies reported that immunotherapy in allergic rhinitis seems to prevent the development of new allergic sensitizations and/or new onset asthma. Humoral-, cellular-, and tissue-level changes occur with allergen immunotherapy, including induction of allergen-specific regulatory T and B cells, interleukin 10, and transforming growth factor β production; suppression of T-helper type 2 cell proliferation; large increases in anti-allergen IgG4 antibodies; and reduction in basophil, mast cell, and eosinophil mediator release. Allergen immunotherapy can be administered either subcutaneously in the physician's office or sublingually by the patient at home. The use of immunotherapy in food allergy is still under investigation.
APA, Harvard, Vancouver, ISO, and other styles
3

Petrova, S. Yu, S. V. Khlgatian, V. M. Berzhets, and A. V. Vasileva. "Allergy vaccines for specific immunotherapy." Journal of microbiology, epidemiology and immunobiology 98, no. 1 (March 4, 2021): 104–12. http://dx.doi.org/10.36233/0372-9311-11.

Full text
Abstract:
Allergen-specific immunotherapy (ASIT) has been used for more than a hundred years to treat patients with IgEmediated allergic diseases. The most common allergens have been obtained using molecular cloning technology in the past two decades. To increase the safety of immunotherapy, a large group of genetically modified allergens with reduced allergenic activity was created. The mechanism of action of these therapeutic allergens differs from natural allergen extracts, and more research is needed to understand how desensitization occurs in each case. The objective of this review is to introduce readers to new therapeutic allergy vaccines and their structural modification features as well as immunological effects on the body. To achieve this objective, we have analyzed and systematized the experimental developments presented in the literature on the main directions of creating new allergy vaccines: hypoallergenic derivatives of recombinant allergens, T cell epitope-based allergy vaccines and B cell epitope-based allergy vaccines, DNA vaccines.Summing up the results of the research presented in the literature, it is necessary to note the high heterogeneity of designs used to achieve the high efficiency of the developed therapeutic allergens. All allergy vaccines presented in the review solve the tasks set by the researchers: in experimental animal models they induce immunogenicity or tolerance, in clinical trials they reduce the symptoms of allergic reactions. The the effectiveness of the proposed medicinal products is quite high but its evaluation requires further long-term preclinical and clinical trials to confirm the safety and harmlessness of the created allergy vaccines.
APA, Harvard, Vancouver, ISO, and other styles
4

Tadjieva, G. Z., O. S. Mirzaev, and Kh N. Shadieva. "Skin Test Results in Patients with Allergies in Samarkand Region." Doctor.Ru 19, no. 11 (2020): 56–60. http://dx.doi.org/10.31550/1727-2378-2020-19-11-56-60.

Full text
Abstract:
Study Objective: To assess skin test results in patients with some allergies. Design: Perspective comparative study. Materials and Methods. We examined 1,963 patients with allergies who presented to Tadjieva Allergo-Medical Service LLC (Samarkand) in 2018–2019. 895 patients consented to and underwent allergy testing with scarification skin tests; they had various allergies (bronchial asthma, allergic rhinoconjunctivitis, allergic bronchitis, atopic dermatitis, urticaria). We used 76 types of most common allergens, including 24 plant allergens, 7 domestic allergens, 13 fungal allergens, 3 epidermal allergens, 27 food allergens, histamine and control test. Results. Most common, positive test results were seen with saltwort (42.9%), plantain (39.5%), wormwood (33.7%), pigweed (26.6%), quitch grass (27.3%), cultivated plant mix (corn, rye, barley, oats, wheat) (41.8%), wild grasses (dart grass, scleranthus, bluegrass, ryegrass, brome grass, couch grass, red-tailed fescue grass, foxtail, timothy) (40.4%). In domestic allergens, the highest number of positive test results accounted for Acarus siro (29.1%), Tyrophagus putrescentiae (24.6%), Dermatophagoides pteronyssinus (21.8%), D. farinae (20.9%) mites. Still, the most severe are the diseases caused by hypersensitivity to fungal allergens Аlternaria alternatа (8.7%), Candida (8.9%). Polyvalent sensibilization was recorded in the majority of cases; but it was not a factor of severity and did not correlated with the duration of the disease. Conclusion. The results allow verifying aetiological factors of allergies in each case; later it can be used for targeted molecular diagnosis and allergen-specific immunotherapy. Keywords: allergies, allergen-specific immunotherapy, skin tests, plant, domestic, fungal allergens, polysensitization.
APA, Harvard, Vancouver, ISO, and other styles
5

Dona, Dulashi Withanage, and Cenk Suphioglu. "Egg Allergy: Diagnosis and Immunotherapy." International Journal of Molecular Sciences 21, no. 14 (July 16, 2020): 5010. http://dx.doi.org/10.3390/ijms21145010.

Full text
Abstract:
Hypersensitivity or an allergy to chicken egg proteins is a predominant symptomatic condition affecting 1 in 20 children in Australia; however, an effective form of therapy has not yet been found. This occurs as the immune system of the allergic individual overreacts when in contact with egg allergens (egg proteins), triggering a complex immune response. The subsequent instantaneous inflammatory immune response is characterized by the excessive production of immunoglobulin E (IgE) antibody against the allergen, T-cell mediators and inflammation. Current allergen-specific approaches to egg allergy diagnosis and treatment lack consistency and therefore pose safety concerns among anaphylactic patients. Immunotherapy has thus far been found to be the most efficient way to treat and relieve symptoms, this includes oral immunotherapy (OIT) and sublingual immunotherapy (SLIT). A major limitation in immunotherapy, however, is the difficulty in preparing effective and safe extracts from natural allergen sources. Advances in molecular techniques allow for the production of safe and standardized recombinant and hypoallergenic egg variants by targeting the IgE-binding epitopes responsible for clinical allergic symptoms. Site-directed mutagenesis can be performed to create such safe hypoallergens for their potential use in future methods of immunotherapy, providing a feasible standardized therapeutic approach to target egg allergies safely.
APA, Harvard, Vancouver, ISO, and other styles
6

Rakhmatullina, N. M., Yu V. Pastushenko, O. R. Trofimova, N. A. Sibgatullina, D. G. Akhmedzyanova, and G. N. Zakirov. "Modern methods of allergen-specific immunotherapy in allergic rhinitis treatment." Kazan medical journal 97, no. 2 (April 15, 2016): 288–94. http://dx.doi.org/10.17750/kmj2016-288.

Full text
Abstract:
The article presents the modern methods of allergen-specific immunotherapy in patients with allergic rhinitis. Allergen-specific immunotherapy - a method of treating allergic diseases, involves reducing the organism’s sensitivity to the allergen effects by repeated administration of allergen extract, starting with the minimum dose. Given the allergic rhinitis high prevalence, as well as its tendency to increase, strong interest in effective methods of its treatment is fully justified. Over the last 20 years, it has become clear that asthma and rhinitis are two types of manifestations of a single pathological process in the airways. It has been proven that allergic disease clinical features may change over time. In addition, patients with allergy are prone to multivalent sensitization. Currently none of the drugs used to relieve allergic rhinitis symptoms can not change the organism’s response to an allergen. Allergen-specific immunotherapy can reduce allergic disease symptoms severity, reduces the need in drugs use, decreases the chance of additional sensitization to other allergens, prevents the asthma development. This therapy has become one of the most widely used effective methods of atopic diseases treatment: seasonal and perennial rhinoconjunctivitis, atopic asthma. Allergen-specific immunotherapy can lead to a change in the immunological response to the relevant allergens in early stages, acting through regulatory cells. Current studies are aimed, on the one hand, at reducing the therapeutic allergovaccines ability to cause allergic reactions, on the other - to maintain or enhance their immunogenic properties. Achieving this goal is possible by changing the route of administration and delivery of therapeutic allergens (non-injection methods of allergen-specific immunotherapy), and using a variety of allergens modification techniques.
APA, Harvard, Vancouver, ISO, and other styles
7

Gordon, Bruce R. "Future Immunotherapy: What Lies Ahead?" Otolaryngology–Head and Neck Surgery 113, no. 5 (November 1995): 603–5. http://dx.doi.org/10.1177/019459989511300512.

Full text
Abstract:
There is currently great interest in developing improved methods of immunotherapy and new techniques of immune system manipulation to ameliorate allergic diseases. This article reviews current research trends in the immunologic treatment of allergy, including the use of chemically modified allergens, nonparenteral allergen exposure, sustained-release allergen delivery, anti-immunoglobulin E antibodies, γ-globulin, immune complexes, cytokines, and T-cell-tolerogenic peptides.
APA, Harvard, Vancouver, ISO, and other styles
8

Roger, Albert, Maria Basagana, Aina Teniente-Serra, Nathalie Depreux, Yanina Jurgens, Clara Padro, Sira Miquel, Carolina Elduque, and Eva M. Martinez-Caceres. "Immunotheraphy in Allergic Diseases." Current Pharmaceutical Design 24, no. 11 (June 27, 2018): 1174–94. http://dx.doi.org/10.2174/1381612824666180116094048.

Full text
Abstract:
The prevalence of allergic diseases is increasing worldwide. It is estimated that more than 30% of the world population is now affected by one or more allergic conditions and a high proportion of this increase is in young people. The diagnosis of allergy is dependent on a history of symptoms on exposure to an allergen together with the detection of allergen-specific IgE. Accurate diagnosis of allergies opens up therapeutic options. Allergen specific immunotherapy is the only successful disease-modifying therapy for IgE-mediated allergic diseases. New therapeutic strategies have been developed or are currently under clinical trials. Besides new routes of administration, new types of allergens are being developed. The use of adjuvants may amplify the immune response towards tolerance to the antigens. In this review, we analyze different antigen-specific immunotherapies according to administration route, type of antigens and adjuvants, and we address the special case of food allergy.
APA, Harvard, Vancouver, ISO, and other styles
9

Pavón-Romero, Gandhi F., Maria Itzel Parra-Vargas, Fernando Ramírez-Jiménez, Esmeralda Melgoza-Ruiz, Nancy H. Serrano-Pérez, and Luis M. Teran. "Allergen Immunotherapy: Current and Future Trends." Cells 11, no. 2 (January 8, 2022): 212. http://dx.doi.org/10.3390/cells11020212.

Full text
Abstract:
Allergen immunotherapy (AIT) is the sole disease-modifying treatment for allergic rhinitis; it prevents rhinitis from progressing to asthma and lowers medication use. AIT against mites, insect venom, and certain kinds of pollen is effective. The mechanism of action of AIT is based on inducing immunological tolerance characterized by increased IL-10, TGF-β, and IgG4 levels and Treg cell counts. However, AIT requires prolonged schemes of administration and is sometimes associated with adverse reactions. Over the last decade, novel forms of AIT have been developed, focused on better allergen identification, structural modifications to preserve epitopes for B or T cells, post-traductional alteration through chemical processes, and the addition of adjuvants. These modified allergens induce clinical-immunological effects similar to those mentioned above, increasing the tolerance to other related allergens but with fewer side effects. Clinical studies have shown that molecular AIT is efficient in treating grass and birch allergies. This article reviews the possibility of a new AIT to improve the treatment of allergic illness.
APA, Harvard, Vancouver, ISO, and other styles
10

De Souza Rebouças, Juliana, Irene Esparza, Marta Ferrer, María Luisa Sanz, Juan Manuel Irache, and Carlos Gamazo. "Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy." Journal of Biomedicine and Biotechnology 2012 (2012): 1–13. http://dx.doi.org/10.1155/2012/474605.

Full text
Abstract:
In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of allergic diseases. However, current allergen immunotherapy shows limitations concerning the long-term efficacy and safety due to local side effects and risk of anaphylaxis. Thus, effective and safe vaccines with reduced dose of allergen have been developed using adjuvants. Nevertheless, the use of adjuvants still has several disadvantages, which limits its use in human vaccines. In this context, several novel adjuvants for allergen immunotherapy are currently being investigated and developed. Currently, nanoparticles-based allergen-delivery systems have received much interest as potential adjuvants for allergen immunotherapy. It has been demonstrated that the incorporation of allergens into a delivery system plays an important role in the efficacy of allergy vaccines. Several nanoparticles-based delivery systems have been described, including biodegradable and nondegradable polymeric carriers. Therefore, this paper provides an overview of the current adjuvants used for allergen immunotherapy. Furthermore, nanoparticles-based allergen-delivery systems are focused as a novel and promising strategy for allergy vaccines.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Allergen immunotherapy"

1

Dandrieux, Julien. "Influence of allergen-specific immunotherapy on allergen-specific IgG subclasses in dogs with atopic dermatitis /." [S.l.] : [s.n.], 2008. http://www.zb.unibe.ch/download/eldiss/08dandrieux_j.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gardner, Leanne M. (Leanne Margaret) 1977. "Modulation of the allergen-specific Tcell response." Monash University, Dept. of Pathology and Immunology, 2003. http://arrow.monash.edu.au/hdl/1959.1/5817.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Beuraud, Chloé. "Identification et caractérisation d'une population de cellules lymphoïdes innées de type 2 (ILC2) associée à la sévérité de la rhinite allergique et de l'asthme." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS475.

Full text
Abstract:
Identification et caractérisation d'une population d'ILC2 associée à la sévérité de la rhinite allergique et de l'asthmeTrois catégories de cellules lymphoïdes innées (innate lymphoid cells, ILC) ont été décrites récemment sur la base de leurs phénotypes et leurs caractéristiques fonctionnelles : les ILC1, ILC2 et ILC3. Les ILC2 semblent avoir un rôle pro-inflammatoire important dans l’allergie en raison de leur capacité à produire de grandes quantités de cytokines TH2.Pour mieux comprendre le rôle de ces cellules dans l’allergie respiratoire, nous avons comparé les ILC sanguines de patients atteints d’une rhinite allergique associée ou non à un asthme, à celles de sujets non allergiques. Cette étude révèle de multiples différences fonctionnelles entre les ILC circulantes de sujets sains et allergiques. Notamment, la fréquence d’ILC2 exprimant le récepteur aux chimiokines CCR10 est augmentée dans le sang de patients asthmatiques sévères.CCR10 pouvant permettre le recrutement des ILC vers les organes cibles, le rôle des ILC2 CCR10+ dans la physiopathologie de l’asthme a été étudié. Leur présence dans les poumons humains a été observée. Des analyses fonctionnelles et phénotypiques ont révélé que cette sous-population cellulaire était peu activée mais présentait une plasticité leur conférant des caractéristiques proches des ILC1. La déplétion de ces cellules dans un modèle murin d’asthme allergique aggrave l’hyperréactivité bronchique.Les travaux de cette thèse documentent le rôle des ILC dans l’asthme. En particulier, la fréquence sanguine d’ILC2 CCR10+ augmente avec la sévérité de la maladie. Les résultats obtenus dans les modèles animaux suggèrent que ces cellules auraient un rôle bénéfique dans le contrôle de l’asthme. La voie du CCR10 pourrait représenter une nouvelle cible pour le développement de traitements innovants contre l’asthme ou une source prometteuse de biomarqueurs
Identification and characterization of an ILC2 subset linked to allergic rhinitis and asthma severityInnate lymphoid cells (ILCs) have been classified into ILC1, ILC2 and ILC3 subsets based on their respective phenotypes and functions. Considering the strong ability of ILC2s to produce TH2 cytokines, these cells likely play a significant role in allergic diseases.To better understand the role of these cells in respiratory allergies, we compared blood ILCs from allergic patients with or without asthma to non-allergic individuals. Together our results show multiple functional differences between ILC from allergic and healthy subjects. In particular, ILC2s expressing the chemokine receptor CCR10 are specifically enriched in the blood of patients with severe allergic asthma.Considering that CCR10 could allow the recruitment of ILCs to target organs, the role of CCR10+ ILC2s in asthma physiopathology has been studied. This ILC2 subtype is present in human lungs. Functional and phenotypic analyses revealed that these cells are less activated than other ILC2s and show ILC1-like properties. CCR10+ ILC2s depletion in a mouse model of allergic asthma exacerbate airway hyperreactivity.Together, this work documents the role of ILCs in asthma. Specifically, circulating CCR10+ ILC2 frequency increases with asthma severity. The results obtained in mouse models suggest that these cells could have a beneficial role in asthma control. CCR10 pathway could represent a new target to elaborate breakthrough treatments against asthma or a source of promising biomarkers
APA, Harvard, Vancouver, ISO, and other styles
4

Gueguen, Claire. "Caractérisation des cellules dendritiques de type 2 : Application à la recherche de biomarqueurs de l’immunothérapie spécifique allergénique." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA114806.

Full text
Abstract:
L’allergie ou l’hypersensibilité de type I est une réponse inappropriée du système immunitaire à une substance étrangère à l’organisme, nommée « allergène ». L’immunothérapie allergénique (ITA) est actuellement le seul traitement sur le marché qui permet de traiter l’étiologie de la maladie allergique par opposition aux traitements symptomatiques qui diminuent temporairement les manifestations allergiques. Son action consiste à réduire la sensibilité de l’organisme vis-à-vis de l’allergène en modulant progressivement la réponse immunitaire dirigée contre ce dernier. L’objectif de cette thèse était de définir des biomarqueurs d’efficacité clinique utilisables dans le cadre des traitements de l’ITA. La stratégie de recherche est basée sur une hypothèse qui consiste à suggérer que les cellules dendritiques (DCs) sont impliquées dans le succès de l’immunothérapie. En particulier, nous supposons que le traitement induit une baisse des DCs de type 2 (DC2), qui induisent des lymphocytes T auxiliaires de type 2 (TH2), et une augmentation des DCs régulatrices (DCreg), qui induisent des lymphocytes T régulateurs. La première partie de cette thèse a consisté à mettre au point des conditions de culture induisant des DC2. Pour cela, un criblage de molécules biologiques et pharmacologiques a été entrepris sur les DCs dérivées des monocytes afin d’induire in vitro des DC2 et a conduit à la mise au point d’un mélange de plusieurs molécules, dont certaines sont impliquées dans les mécanismes de l’allergie. Le phénotype des DC2 obtenu a été étudié ainsi que la polarisation des lymphocytes T induite après co-cultures en comparaison avec des DCs de type 1 (DC1) et des DCreg.La deuxième partie de cette thèse a consisté à analyser, à l’échelle moléculaire, les différents types de DCs induites (DC1, DC2 et DCreg). Pour cela, deux techniques ont été utilisées, une analyse transcriptomique par puces à ADN et une analyse protéomique par spectrométrie de masse sans marquage, pour comparer le transcriptome et le protéome des DCs induites. Le différentiel d’expression des marqueurs les plus pertinents a été validé au niveau transcriptionnel et protéique.Dans la troisième partie de cette thèse, le suivi des marqueurs dans des cellules du sang de patients allergiques traités ou non par ITA lors d’une étude clinique randomisée, contrôlée, en double aveugle, a permis de définir six nouveaux candidats biomarqueurs d’efficacité de l’immunothérapie, dont trois spécifiques des DC2 et trois autres spécifiques des DCreg. Ces marqueurs pourront être suivis lors des traitements d’ITA pour distinguer les patients répondeurs des non-répondeurs
Allergy or type I hypersensitivity is an inappropriate response of the immune system to a foreign substance in the body, called "allergen". Allergen immunotherapy (AIT) is currently the only treatment on the market that can handle the etiology of allergic disease versus symptomatic treatments that temporarily reduce allergic manifestations. Its action is to reduce the sensitivity of the body against allergens.The aim of this thesis was to define biomarkers of clinical efficacy of AIT. The research strategy is based on the following hypothesis: dendritic cells (DCs) are involved in the success of immunotherapy. In particular, we assume that the treatment induces a decrease in DCs type 2 (DC2), which induce type 2 helper T cells, and an increase of regulatory DCs (DCreg), which induce regulatory T cells.First, we defined optimal culture conditions inducing the polarization of in vitro immature monocyte-derived DCs (MoDCs) toward a DC2 pattern. After screening several biological and pharmaceutical agents, we selected a cocktail of six molecules with some of them are pro-allergenic molecules. The phenotype of those DC2 cells and the CD4+ T cell polarization induced after coculture were characterized extensively in comparison with type 1 DC (DC1) and DCreg.In a second part, we compared the transcriptomes and the proteomes of MoDCs polarized into DC1, DC2 and DCreg by using cDNA microarrays together with label-free mass spectrometry. The differential expression of the most relevant markers was confirmed at the transcriptional and protein level. In the third part, markers were also followed in the peripheral blood from allergic patients enrolled in a randomized, double-blind, placebo-controlled AIT study. The expression of three DC2 markers was down-regulated and of three DCreg markers was up-regulated in patients who responded to the treatment and correlated with clinical efficacy. These markers could be used as follow-up read-outs of AIT efficacy in order of to discriminate responders from nonresponders
APA, Harvard, Vancouver, ISO, and other styles
5

Lee-Fowler, Tekla. "Determination of allergen sensitization and comparison of subcutaneous and mucosal (intranasal) allergen-specific immunotherapy in an experimental model of feline asthma." Diss., Columbia, Mo. : University of Missouri-Columbia, 2009. http://hdl.handle.net/10355/6723.

Full text
Abstract:
Thesis (M.S.)--University of Missouri-Columbia, 2009.
The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. "May 2009" Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
6

Nony, Emmanuel. "Production et caractérisation de l'allergène recombinant Bet v 1 utilisé à des fins d'immunothérapie allergénique." Thesis, Paris 11, 2015. http://www.theses.fr/2015PA114801.

Full text
Abstract:
L'allergie respiratoire au pollen de bouleau affecte un nombre important de personnes dans le monde. Il est estimé que 100 millions d'individus sont sensibilisés à l'allergène majeur du pollen de bouleau nommé Bet v 1. L’immunothérapie allergénique, basée sur l'administration répétée de l'allergène incriminé, permet la rééducation du système immunitaire du patient d’un profil TH2 vers un profil TH1/Treg et à terme la diminution des symptômes allergiques. Ces travaux de thèse avaient donc pour finalité de produire et de caractériser l'allergène recombinant Bet v 1, à des fins d’immunothérapie allergénique. Dans ce cadre, différentes méthodes analytiques ont été développées et appliquées afin d'optimiser le procédé de production via l'élimination de différentes impuretés liées au produit ou au procédé de production et de documenter la structure de l’allergène. En particulier, l'utilisation de la spectrométrie de masse a permis la détermination de la masse exacte de l'allergène ainsi que la vérification complète de sa séquence en acides aminés. Les travaux en spectrométrie de masse ont également contribué aux détections et identifications de diverses impuretés et produits de dégradations et ont ainsi conduit à plusieurs optimisations du procédé industriel de production de l'allergène recombinant. Les activités immunologiques de certains produits de dégradations ont également été investiguées. La structure tertiaire (spatiale) de l'allergène a été déterminée par diffraction aux rayons X. Enfin, ces travaux ont permis de documenter la qualité de l'allergène recombinant rBet v 1 afin i) de l'établir comme substance de référence pour la Pharmacopée Européenne et ii) de procéder à une étude clinique d’immunothérapie allergénique de phase II auprès de 483 patients allergiques au pollen de bouleau
Respiratory allergy to birch pollen affects a large number of people in the world. It is estimated that 100 million people are sensitized to the major allergen from birch pollen, namely Bet v 1. Allergen immunotherapy, based on the repeated administration of the allergen of interest, allows the modification of the patient's immune response from a TH2 to a TH1/Treg pattern and thus the reduction of allergic symptoms. This study was therefore aimed to produce and characterize the recombinant Bet v 1 (rBet v 1) allergen, for immunotherapy purpose.In this context, various analytical methods have been developed and applied in order to optimize the production of rBet v 1 via the reduction of process or product-related impurities as well as to document the quality of the purified allergen. In particular, the use of mass spectrometry has allowed the determination of the exact mass of the intact allergen and the complete verification of its amino acid sequence. Mass spectrometry data have also contributed to the detection and identification of impurities and degradation products and have therefore led to several optimizations of the industrial process for the production of the recombinant allergen. Immunological activities of certain degradation products were also investigated and the allergen tertiary structure was determined by X-ray diffraction. Finally, this study was decisive in order i) to establish rBet v 1 as a chemical reference substance for the European Pharmacopoeia as well as ii) to perform a phase II clinical study conducted in 483 patients with birch pollen-induced rhinoconjunctivitis
APA, Harvard, Vancouver, ISO, and other styles
7

Sayers, Rebekah. "Proteomic profiling of processing-induced modifications to food proteins." Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/proteomic-profiling-of-processinginduced-modifications-to-food-proteins(f6560c3b-4f80-49b9-94c2-6cd9b41288fa).html.

Full text
Abstract:
Peanut allergy typically results from sensitisation to one or more integral seed storage proteins; Ara h 1, 3 or 2/6. Reactions can be triggered by as little as 3 mg protein in 10% of allergic individuals and are often severe, inducing anaphylaxis which can be fatal. Accidental exposure through unintended presence can therefore be hazardous and foods must be labelled appropriately. Thermal processing is one of the main factors affecting protein properties in food systems, including the formation of Maillard reaction products. Research has suggested a link between the allergenicity of foods and cooking methods employed. A systematic study was undertaken to assess the thermal dependence of these hazard proteins, focusing on changes to solubility and chemical modifications which may alter IgE binding. Proteomic profiling was used to assess the allergenic content of peanut products and develop alternative methods for allergen analysis to support evidence-based application of precautionary allergen labelling. Runner variety peanuts were processed (boiled, fried, roasted) and their protein content determined. Proteins extracts were characterised by 1D- and 2D-polyacrylamide gel electrophoresis, including differential in-gel electrophoresis. Proteomic profiling was undertaken using label-free analysis to assess allergen composition and investigate the formation of Maillard reaction products on the most clinically relevant proteins. Peanut allergen peptide targets were then identified and used to develop label-based quantitation methods and applied to (i) investigate effects of processing on peptide targets and (ii) determine peanut in chocolate products in comparison with a commercial ELISA kit. Orthogonal studies were performed using serum samples from peanut allergic patients obtained from the Manchester Respiratory, Allergy and Thoracic Surgery (ManARTS) Biobank. Patient IgE reactivity to peanut and processed peanut products was assessed by immunoblotting, inhibition ELISA and mediator release assays. Protein solubility was reduced by thermal processing and processed protein required harsh denaturing conditions for extraction. Qualitative analysis highlighted decreased solubility of key allergens, modifications and aggregation after heating. Proteomic profiling identified and quantified different isoforms of the major peanut allergens. The protein content of processed peanuts was reduced by boiling, specifically the 2S albumins, which transferred into the cooking water. The performance of peptides selected for targeted MRM experiments was influenced by thermal processing and the presence of cocoa phenolics. Ara h 2 peptides flanked by arginine were thermostable and may prove more reliable for quantification. Application of microfluidic separation enhanced the efficiency of target ionisation in complex matrices acquiring important sensitivity gains. Maillard modifications to clinically relevant proteins Ara h 2/6 were found within IgE binding domains in raw and processed peanuts. IgE reactivity studies confirmed reduced IgE binding capacity of extensively boiled peanut and hydrolysed protein, but this did not correlate to a reduction in mediator release in poly-sensitised patients. While effective extraction limits the efficacy of analyses, buffers used in MS analyses are more robust in analysing processed protein. Proteomic profiling provides a means of characterising and profiling of allergenic proteins including food ingredients used in clinical applications. Peptides selected for targeted analyses should be validated to assess their suitability in model foods. Cooking waters collected from extensively boiled peanuts may provide an alternative and safer immunotherapy agent for patients predominantly sensitised to Ara h 2/6.
APA, Harvard, Vancouver, ISO, and other styles
8

Scadding, Guy. "Nasal allergen provocation : validation of clinical and immunologic markers and response to grass pollen immunotherapy." Thesis, Imperial College London, 2015. http://hdl.handle.net/10044/1/33795.

Full text
Abstract:
Background: Allergen-specific immunotherapy is an effective treatment for seasonal allergic rhinitis. Clinical trials may be confounded by variable allergen exposure. Nasal allergen provocation might provide a useful surrogate to assess the efficacy of immunotherapy and identify biomarkers of response. Objective: Nasal allergen provocation was used to assess the efficacy of allergen immunotherapy and identify local and systemic immune biomarkers. Methods: Dose and time course responses to grass-pollen nasal provocations were studied in 20 allergic individuals. Different matrices were compared for absorption and isolation of nasal mucosal fluid for immunoassay of inflammatory mediators. Optimised techniques were then applied to cat-allergen nasal provocation in 18 allergic individuals, along with assessment of in vitro basophil allergen-induced activation. Finally, in a cross-sectional study, responses to grass-pollen provocation were compared in 14 untreated grass-pollen allergics, 18 immunotherapy-treated patients, and 14 non-atopic controls. Results: Nasal responses to allergen were dose-dependent. Symptoms peaked at 5 minutes post challenge; overall, there was no distinct late-phase clinical response. Nasal fluid tryptase peaked at 5 minutes; IL-4, -5, -9, -13 and eotaxin peaked at 8 hours. Basophil allergen-induced activation in vitro was enhanced at 6 hours compared to pre-challenge. Grass-pollen immunotherapy-treated patients had lower symptom scores (45% lower, p=0.04) and higher peak nasal inspiratory flow, PNIF (54% higher, p=0.02) after challenge than untreated-allergics. They had reduced early (27% lower, p=0.0007) and late (51% lower, p < 0.0001) skin responses, and lower retrospective seasonal symptom scores (60% lower, p < 0.0001). Nasal challenge response correlated with seasonal symptoms (symptoms: r=0.52, p < 0.003; PNIF: r=-0.57, p < 0.001). Immunotherapy-treated patients had reduced nasal fluid IL-4, IL-9 and eotaxin (p < 0.05), and trends for reduced IL-13 and tryptase levels (p=0.07). Conclusions: Nasal allergen challenge is sensitive in the detection of clinical and biological effects of allergen immunotherapy and may be a useful surrogate marker of treatment efficacy in future studies.
APA, Harvard, Vancouver, ISO, and other styles
9

Junebjörk, Lydia, and Johanna Marstorp. "Patienters upplevelser av allergenspecifik immunterapi." Thesis, Uppsala universitet, Institutionen för folkhälso- och vårdvetenskap, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-294566.

Full text
Abstract:
Introduktion: I Sverige har det uppmätts att 27% av befolkningen har en luftvägsallergi. Dessa behandlas främst med symtomlindrande läkemedel men när detta inte räcker till kan allergenspecifik immunterapi (ASIT) övervägas. Denna behandling kan ges antingen sublingualt eller med subkutana injektioner. Den första studien om ASIT publicerades 1911 och sedan dess har många studier gjorts angående dess effekter. Syfte: Syftet med studien var att undersöka patienters upplevelser av subkutan immunterapi (SCIT). De områden som belystes var upplevelsen av information och kommunikation, psykisk och fysisk påverkan av biverkningar samt hur behandlingen inverkar på vardagen. Metod: En kvalitativ studiedesign användes och data samlades in med hjälp av semistrukturerade intervjuer. Ett bekvämlighetsurval gjordes på en allergimottagning i Mellansverige och tio personer intervjuades. Resultat: Behandlingen påverkade somliga delar av vardagen i viss mån, till exempel att det är tidskrävande och att den fysiska aktiviteten blir begränsad under behandlingsdagen. En del biverkningar förekom, främst allmänna och lokala. Dessa hade viss påverkan på vardagen relaterat till exempelvis trötthet och koncentrationssvårigheter. Kontakten med mottagningen upplevdes positivt och informationen som erhölls inför behandlingsstart upplevdes som tillräcklig. Dock framkom att informationen kring allvarligare biverkningar inte nått fram till alla. Slutsats: Både de upplevda biverkningarna och behandlingen som helhet hade en viss påverkan på patienternas vardag. Kommunikationen och informationen från vården upplevdes överlag positivt. Vidare forskning inom området behövs för att kunna avgöra om dessa resultat är överförbara till en bredare population.
Introduction: It has been measured that 27% of the population in Sweden has a respiratory allergy. Primarily this is treated symptomatically with medication but in cases where this do not work, allergen specific immunotherapy (ASIT) can be considered. ASIT can be administered either sublingually or subcutaneously. The first study acknowledging ASIT was published in 1911 and since then many studies have been performed regarding its effects.      Aim: The aim of this study was to examine patients experiences of subcutaneous immunotherapy (SCIT). This included how patients experienced information and communication, how side-effects affected patients physically and psychologically and how the treatment affected the patients’ everyday life.  Methods: A qualitative study design was used and data was collected with semi-structured interviews. A convenience sample was made at an allergy reception in central Sweden and ten people were interviewed. Results: Parts of the patients’ everyday life were affected to some extent, for example because the treatment is time consuming and that the physical activity has to be limited during the same day as the injection is given. Some side-effects occurred, primarily general and local ones. These affected the everyday life in the sense that the patients felt tired and experienced difficulty concentrating. The contact with the reception was described in a positive manner and the information received before starting treatment was described to be enough. Although the information regarding serious side-effects had not been reached by everyone. Conclusion: Both the experienced side-effects and the treatment in its whole had a certain impact on the patients’ everyday life. The patients described the communication and the information in a positive way. More studies need to be performed in this field to be able to determine whether these results are transferable to a broader population.
APA, Harvard, Vancouver, ISO, and other styles
10

Pinto, Marta. "Epicutaneous immunotherapy as a novel route of allergen administration in dogs with atopic dermatitis : a proof-of-concept study." Master's thesis, Universidade de Lisboa, Faculdade de Medicina Veterinária, 2021. http://hdl.handle.net/10400.5/22140.

Full text
Abstract:
Dissertação de Mestrado Integrado em Medicina Veterinária
ABSTRACT - Allergen immunotherapy is a well-established treatment for canine atopic dermatitis (CAD), but new non-invasive, safe, effective and at-home easy-to-use vaccine-delivery routes that promote compliance are needed. Epicutaneous immunotherapy (EPIT) is a new promising alternative route that takes advantage of the skin’s unique immunological features and high accessibility. Our goal was to assess the feasibility, efficacy, and safety of EPIT in CAD. Sixteen dogs (9 French bulldog (FB) and 7 labrador retriever (LR) dogs) with spontaneous non seasonal CAD and positive allergen-specific IgE (sIgE) serology for domestic mites (HDM) were enrolled for a weekly, 12-hour allergen-containing patch application, over 12 weeks. A costume-made 3D-printed device was developed to incorporate the allergen-based formulation, which included a tailor-made vehicle to enhance allergen penetration into the skin. The primary efficacy outcomes were the owner-assessed pruritus manifestations (PVAS10), veterinarian-assessed skin lesions (2D-IGA), and the owner’s perceived treatment efficacy (OGATE and OGES). Secondary efficacy outcomes were the quality-of-life (QoL), sIgE and IL 10 concentrations. The EPIT safety evaluation considered both local and systemic adverse reactions. Treatment efficacy was defined by the primary outcome measures’ success, according to the ICADA’s COSCAD’18 recommendations. EPIT was deemed safe if no severe local and systemic side-effects occurred. The owner’s compliance with the proposed protocol and required study appointments were monitored and their overall satisfaction was estimated. One LR dog dropped out. All dogs improved their pruritus scores, and 13/15 dogs (86.67%) were successful in the terms considered for this study [FB=8/9 (88.89%); LR=5/6 (83.33%)]. Moreover, 8/12 dogs [66.67%; FB=5/8 (62.5%); LR=3/4 (75%)] reached the level considered successful in the skin lesions’ sore. The response to EPIT was rated as good-to-excellent by 13/15 owners (86.67%) in the OGATE survey and by 11/15 owners (73.33%) in the OGES survey. An improvement in the QoL scores was reported by 13/15 owners (86.67%), with a percentage mean improvement of 54.58%. sIgE values overall decreased in 10/15 dogs (66.67%) and 2/15 dogs (13.33%) desensitised to all HDM to which they were previously allergic. Non-conclusive IL-10 results were obtained. No systemic or local severe adverse events were recorded. EPIT was well received by the owners of the 15 dogs, who fully complied with the proposed protocol. This pilot study emphasizes the EPIT’s great potential as an effective and safe CAD treatment, supporting further investigation on this novel therapy.
RESUMO - Imunoterapia epicutânea como uma nova via de administração de alergénios em cães com dermatite atópica : uma prova de conceito - A imunoterapia com alergénios é um tratamento bem estabelecido para a dermatite atópica canina (CAD), mas são necessárias novas vias não invasivas, seguras, eficazes e de fácil administração em casa que promovam a adesão à terapia. A imunoterapia epicutânea (EPIT) é uma via promissora que beneficia da grande acessibilidade e das características imunológicas únicas da pele. O objetivo deste estudo foi avaliar a praticabilidade, eficácia e segurança da EPIT na CAD. Foram recrutados dezasseis cães (9 cães bouledogue francês (FB) e 7 labrador retriever (LR)) com CAD espontânea não sazonal e com serologia de IgE alergénio-específica (sIgE) positiva para ácaros domésticos (HDM) para a aplicação semanal de um penso de 12 horas, durante 12 semanas. Para o efeito foi impresso um dispositivo em 3D para incorporar a formulação alergénica, a qual incluía um veículo desenvolvido para aumentar a penetração dos alergénios na pele. A avaliação da eficácia utilizou parâmetros primários – a avaliação do prurido pelo titular do cão (PVAS10), das lesões cutâneas pelo veterinário (2D-IGA) e a perceção dos titulares sobre a eficácia da terapêutica (OGATE e OGES) – e parâmetros secundários – grau de qualidade de vida e concentrações de sIgE e IL-10. Para a avaliação da segurança foram consideradas reações sistémicas e locais. A eficácia da EPIT foi definida pelo sucesso dos parâmetros primários, de acordo com as recomendações COSCAD’18 do ICADA. A EPIT foi considerada segura se não ocorressem reações sistémicas ou locais graves. Foram ainda registados o cumprimento do protocolo, a comparência dos titulares às consultas do estudo e a sua satisfação global com o tratamento. Um titular de LR desistiu do estudo. Todos os cães melhoraram o grau de prurido, dos quais 13 (86.67%) alcançaram o nível considerado de sucesso [FB=8/9 (88.89%); LR=5/6 (83.33%)]. Além disso, 8 dos 12 cães [66.67%; FB=5/8 (62.5%); LR=3/4 (75%)] alcançaram o nível considerado de sucesso no parâmetro de lesões cutâneas. A resposta à EPIT foi classificada como boa-a-excelente por 13 titulares (86.67%) no OGATE e por 11 titulares (73.33%) no OGES. Verificou-se ainda uma melhoria da qualidade de vida em 13 cães (86,67%), com uma melhoria percentual média de 54.58%. Os valores de sIgE diminuíram globalmente em 10 cães (66.67%) e 2 deles (13.33%) dessensibilizaram a todos os HDM aos quais eram alérgicos. Os resultados da IL-10 foram inconclusivos. Não se verificaram quaisquer reações sistémicas nem locais graves. A EPIT foi bem recebida pelos titulares dos 15 cães, os quais cumpriram criteriosamente o protocolo. Este estudo piloto destaca o potencial da EPIT como um tratamento eficaz e seguro para a CAD e encoraja a investigação futura nesta nova terapia.
Supported by LETIPharma Animal Health S.L.U. (Barcelona, Spain)
N/A
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Allergen immunotherapy"

1

Lockey, Richard F., and Dennis K. Ledford, eds. Allergens and Allergen Immunotherapy. Sixth edition. | Boca Raton : CRC Press/Taylor and Francis Group, [2020]: CRC Press, 2020. http://dx.doi.org/10.1201/9781351208994.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sehon, Alec, Kent T. HayGlass, and Dietrich Kraft, eds. New Horizons in Allergy Immunotherapy. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4615-5855-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

International, Paul-Ehrlich-Seminar (12th 2008 Bad Homburg vor der Höhe Germany). Regulatory control and standardization of allergenic extracts: 12th International Paul-Ehrlich-Seminar, September 24 - 27, 2008, Hotel Steigenberger, Bad Homburg, Bad Homburg, Germany. Wiesbaden: Chmielorz, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rebyū-sha, Medikaru. Hana arerugī furontia. Tōkyō: Medikaru Rebyū-sha, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pawankar, Ruby. Allergy frontiers. New York: Springer, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

T, Holgate Stephen, Rosenwasser Lanny J, and SpringerLink (Online service), eds. Allergy Frontiers: Clinical Manifestations. Tokyo: Springer Japan, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Symposium in Immunology (4th 1994 Heidelberg, Germany). Symposium in immunology IV: Allergic diseases. Berlin: Springer-Verlag, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wierenga, Edsko Albert. Functional subsets of T helper cells: Implications for allergic disease. [Amsterdam: University of Amsterdam, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pawankar, Ruby. Allergy Frontiers: Diagnosis and Health Economics. Tokyo: Springer Japan, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gaetano, Melillo, O'Byrne Paul M. 1951-, and Marone G, eds. Respiratory allergy: Advances in clinical immunology and pulmonary medicine : proceedings of the III International Meeting on Respiratory Allergy, Naples, 1-4 April 1992. Amsterdam: Excerpta Medica, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Allergen immunotherapy"

1

Ashok, S., and P. Vedanthan. "Allergen Immunotherapy." In Allergy and Allergen Immunotherapy, 427–53. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315207520-24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Fox, Roger W., and Richard F. Lockey. "Allergen Immunotherapy." In Allergic Diseases, 421–36. Totowa, NJ: Humana Press, 2000. http://dx.doi.org/10.1007/978-1-59259-007-0_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wilson, Duncan R., and Stephen R. Durham. "Allergen Immunotherapy." In New Drugs for Asthma, Allergy and COPD, 186–90. Basel: KARGER, 2001. http://dx.doi.org/10.1159/000062191.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Codina, Rosa, and Richard F. Lockey. "Allergen Immunotherapy." In Atlas of Allergic Diseases, 161–70. London: Current Medicine Group, 2002. http://dx.doi.org/10.1007/978-1-4615-6481-2_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Edakalavan, Jyothi, and Ravindran Chetambath. "Allergen Immunotherapy." In Clinical Allergy and Asthma Management in Adolescents and Young Adults, 243–50. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003125785-31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nelson, Harold S. "Allergen Immunotherapy." In Textbook of Allergy for the Clinician, 165–77. 2nd ed. Second edition. | Boca Raton : CRC Press, 2021.: CRC Press, 2021. http://dx.doi.org/10.1201/9780367854706-15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Feteih, Abeer, Walaa Almasri, Geneviève Genest, Hoang Pham, and Phil Gold. "Allergen Immunotherapy." In The Manual of Allergy and Clinical Immunology, 31–38. Boca Raton: CRC Press, 2021. http://dx.doi.org/10.1201/9781003174202-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kanni, Paranjothy, Nagendra Komarla, and A. Singh. "Sublingual Immunotherapy." In Allergy and Allergen Immunotherapy, 455–67. Taylor & Francis Group, 6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC Press, 2017. http://dx.doi.org/10.1201/9781315207520-25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Breiteneder, Heimo, Rick Goodman, Martin D. Chapman, and Anna Pomés. "Allergen nomenclature." In Allergens and Allergen Immunotherapy, 49–63. Sixth edition. | Boca Raton : CRC Press/Taylor and Francis Group, [2020]: CRC Press, 2020. http://dx.doi.org/10.1201/9781351208994-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wallace, Dana V., and John Oppenheimer. "Adherence and cost-effectiveness of subcutaneous immunotherapy and sublingual immunotherapy." In Allergens and Allergen Immunotherapy, 449–70. Sixth edition. | Boca Raton : CRC Press/Taylor and Francis Group, [2020]: CRC Press, 2020. http://dx.doi.org/10.1201/9781351208994-31.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Allergen immunotherapy"

1

Filipovic, Ivana, Zorica Zovkovic, Djordje Filipovic, Vesna Vekovic, and Olivera Ostojic. "Sublingual allergen specific immunotherapy in children with respiratory allergies – long lasting efficacy." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Peiyan, Zheng, and Baoqing Sun. "Collaborative treatment with variety of dust mites allergic in standardized dermatophagoides pteronyssinus allergen immunotherapy." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4202.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ereshko, Oksana, Leyla Namazova-Baranova, Elena Vishneva, Svetlana Makarova, Marina Snovskaya, Julia Levina, Kamilla Efendieva, and Anna Alekseeva. "Allergen specific immunotherapy efficacy in children with pollen-food allergy syndrome and different IgE profiles to recombinant component-resolved allergens." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa4036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yilmaz, Ozge, Adem Yaşar, Yurda Simsek, Sedef Alpdogan, Bora Kunay, and Hasan Yuksel. "Effect of subcutaneous allergen immunotherapy on the natural course of allergic diseases: a retrospective cohort study." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa943.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lazarenko, Lyudmila, Galina Sergeeva, and Elena Lazutkina. "Allergen immunotherapy modulates pro- and antioxidant status patients with bronchial asthma." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kuropatenko, Mary, Natalia Platonova, Zarrina Azamova, Elizaveta Agapova, and Ludmila Zhelenina. "The allergen-specific immunotherapy efficiency in dependent on patient's parasitic status." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kuprys-Lipinska, Izabela R., Damian Tworek, Malgorzata Dzieciol, Malgorzata Bochenska-Marciniak, Ewa Zielinska-Wyderkiewicz, Izabela Bogus-Buczynska, Monika Antczak-Marczak, Jadwiga Kaczmarek, and Piotr Kuna. "Allergen Immunotherapy As A Treatment Option For Allergic Patients Over 50 Years Old – Patients And Doctors Assessment." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4215.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Filipovic, Ivana, Zorica Zivkovic, Djordje Filipovic, and Gordana Kostic. "Allergen specific immunotherapy: Effect on immunological markers and clinical outcomes in asthmatic children." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa1242.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

COLOMBO, PAOLO, ANTONINO TRAPANI, DOMENICO GERACI, MASSIMILIANO GOLINO, FABRIZIO GIANGUZZA, and ANGELA BONURA. "FROM ALLERGEN BACK TO ANTIGEN: A RATIONAL APPROACH TO NEW FORMS OF IMMUNOTHERAPY." In Proceedings of the 6th International Workshop on Data Analysis in Astronomy “Livio Scarsi”. WORLD SCIENTIFIC, 2007. http://dx.doi.org/10.1142/9789812779458_0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bochenska-Marciniak, M., D. Tworek, M. Kupczyk, E. Bogacka, I. Kuprys-Lipinska, and P. Kuna. "The Effectiveness of Allergen Immunotherapy Depending on the Regimen on Rhinoconjunctivitis and Asthma Symptoms in Allergy to Grass Pollen." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2781.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Allergen immunotherapy"

1

Chen, Ru, Yao Sun, and Guoqi Sima. Comparative efficacy and tolerance of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis: a network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0078.

Full text
Abstract:
Review question / Objective: What is the effect of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis. Condition being studied: Immunotherapy is the classic treatment for allergic rhinitis. Intralymphatic immunotherapy is a new type of treatment. Currently, no studies have compared subcutaneous, sublingual and intralymphatic sublingual immunotherapy. At present, there is no review to compare the efficacy of intralymphatic, subcutaneous and sublingual immunotherapy for pollen-induced allergic rhinitis.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Allergen immunotherapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography